Pharmafile Logo

Ridgeback Biotherapeutics

- PMLiVE

UK announces COVID boosters for a “bumpy winter” ahead

A single shot of Pfizer’s COVID-19 vaccine will be offered to 30 million people in the UK including those 50 or over and frontline health and social care workers

Health literacy in the time of COVID-19

In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...

Impetus Digital

- PMLiVE

Valneva shares fall as UK cancels COVID-19 vaccine order

The UK government has cancelled a supply agreement for French vaccine maker Valneva’s COVID candidate VLA2001 over an alleged breach of obligations.

- PMLiVE

Dovetail wins Communiqué Agility and Flexibility award at Communiqué 2021

This inaugural award was given to Dovetail amid fierce competition from four other agencies

Transitioning to the “New Normal”: What This Means for Oncology Care

Dr. Burt Zweigenhaft, Co-founder of the Association for Value-Based Cancer Care, shares his thoughts on the importance of patient-centricity in cancer care, current barriers to value-based care in the US...

Impetus Digital

- PMLiVE

Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention

The MOVe-AHEAD trial will test whether the drug prevents infection in those living in the same household as someone with confirmed COVID-19

- PMLiVE

FDA’s director and deputy director of its Office of Vaccines Research & Review resign

The departure of director Marion Gruber and deputy director Philip Krause is unexpected

- PMLiVE

GSK/SK bioscience COVID-19 vaccine to enter phase 3 trial

The study will be one of the first global phase 3 trials to compare two different COVID-19 vaccine candidates

News:

Therapy Watch COVID-19 tracker

Research Partnership

- PMLiVE

US demand for COVID-19 antibody treatments rising fast

With the ‘fourth wave’ of COVID-19 in the US, Regeneron and GSK report high demand for their monoclonal antibody treatments

- PMLiVE

Merck’s Keytruda gains two more approvals in Japan

New approvals in breast and colorectal cancer take the number of indication for the immunotherapy mega-blockbuster to 15 in Japan

- PMLiVE

Pfizer/BioNTech file for FDA approval for COVID-19 booster jab

New data shows third dose boosts antibodies by more than three times

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links